Of these drug delivery systems, liposome-based agents will have the greatest impact in neurology. Current liposomal drugs evolve from a number of design strategies for the improvement in biodistribution over free drugs. Reticuloendothelial system-targeted formulations significantly reduce systemic exposure to high peak levels of free drug but do not facilitate targeting to brain. Passive or physiologic targeting of drugs to brain regions is achievable Inhibitors,research,lifescience,medical using long-circulating liposomes, including pure lipid systems as well as surface-modified
formulations designed to resist recognition and uptake by reticuloendothelial system cells. The neurodegeneration of the Alzheimer’s disease and Parkinson’s disease has not been beneficially treated by classical oral therapy. Levodopa for Parkinson’s disease and rivastigmine for Alzheimer’s disease remain the gold standard for the therapy. The design and development Inhibitors,research,lifescience,medical of an alternative drug based on new technologies will have a key role in the systemic application of new drugs, such as, growth factors, peptides or hormones. Nowadays is impossible to treat correctly many diseases mainly for the localization of damaged tissue Inhibitors,research,lifescience,medical or the complexity of tissue this website affected. The complexity of the disease and, many times, the localization of the tissue damage, difficult the possible treatment, for example,
the brain is isolated by the BBB. It is well demonstrated that the application of neurotrophic factors is able to modulate neuronal survival and synaptic connectivity, and it
is a promising therapeutic approach for these neurodegenerative diseases. Although, it is very difficult to ensure long-term administration into the brain, liposome technology Inhibitors,research,lifescience,medical allows us to facilitate transport across the BBB. Liposomes have been used clinically as delivery systems for therapeutic drug delivery of chemotherapeutic agents, antibiotics, and antifungals. This is because liposomal preparations have been shown to increase the margin of safety of many drugs and also their efficacy. Among all the applications Inhibitors,research,lifescience,medical of liposomal technology, the development of a suitable liposomal carrier to encapsulate neuroactive Parvulin compounds is very promising. These liposomes are stable enough to be carried to the brain across the BBB, with the appropriate surface characteristics for an effective targeting and for an active membrane transport. Improvements and adjustments to the liposomal formulation are constantly being explored through the addition of different lipids and targeting molecules. For example, in liposomes lacking cholesterol, high-density lipoprotein can cause disintegration of the liposome, or in liposomes which do contain too much cholesterol, high-density lipoprotein can also cause leakage of contents. The development of novel therapeutic strategies for neurodegenerative and neurological diseases represents one of the biggest unmet medical needs today.